Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86662
Title:
Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.
Authors:
Renehan, Andrew G; Jones, J; Potten, Christopher S; Shalet, Stephen M; O'Dwyer, Sarah T
Abstract:
This study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal colonoscopy (controls). Serial changes were examined in 27 cases. As IGF-related peptides are age- and sex-dependent, absolute concentrations were converted to standard deviation scores (SDS). Mean IGF-II SDS were elevated in Dukes A (n = 12, P< 0.001) and Dukes B (n = 25, P< 0.001) cases compared with controls, but not in advanced disease. Compared with controls, mean IGFBP-2 SDS were significantly elevated in patients with Dukes B (P< 0.001), Dukes C (n = 13, P< 0.001) and advanced disease (n = 42, P< 0.0001), with a significant trend from early to advanced disease (one-way ANOVA, P< 0.001). Furthermore, IGFBP-2 SDS were positively related to tumour size (P = 0.01) and fell significantly in patients following curative resection (P = 0.04), suggesting that circulating levels reflect tumour load. We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. The sensitivities for IGFBP-2 alone (>/= + 2SD) were modest at 55%, 46%, and 52%, but in combination with CEA, increased substantially to 90%, 77% and 86%, respectively. We conclude that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer.
Affiliation:
Department of Surgery, Christie Hospital NHS Trust, Manchester, M20 4BX.
Citation:
Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. 2000, 83 (10):1344-50 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Nov-2000
URI:
http://hdl.handle.net/10541/86662
DOI:
10.1054/bjoc.2000.1462
PubMed ID:
11044360
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew Gen
dc.contributor.authorJones, Jen
dc.contributor.authorPotten, Christopher Sen
dc.contributor.authorShalet, Stephen Men
dc.contributor.authorO'Dwyer, Sarah Ten
dc.date.accessioned2009-11-23T11:10:40Z-
dc.date.available2009-11-23T11:10:40Z-
dc.date.issued2000-11-
dc.identifier.citationElevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. 2000, 83 (10):1344-50 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid11044360-
dc.identifier.doi10.1054/bjoc.2000.1462-
dc.identifier.urihttp://hdl.handle.net/10541/86662-
dc.description.abstractThis study explored the relationships of serum insulin-like growth factors, IGF-I and IGF-II, and their binding proteins (IGFBP)-2 and IGFBP-3, with key clinicopathological parameters in 92 patients with colorectal cancer (cases). Comparisons were made with 57 individuals who had a normal colonoscopy (controls). Serial changes were examined in 27 cases. As IGF-related peptides are age- and sex-dependent, absolute concentrations were converted to standard deviation scores (SDS). Mean IGF-II SDS were elevated in Dukes A (n = 12, P< 0.001) and Dukes B (n = 25, P< 0.001) cases compared with controls, but not in advanced disease. Compared with controls, mean IGFBP-2 SDS were significantly elevated in patients with Dukes B (P< 0.001), Dukes C (n = 13, P< 0.001) and advanced disease (n = 42, P< 0.0001), with a significant trend from early to advanced disease (one-way ANOVA, P< 0.001). Furthermore, IGFBP-2 SDS were positively related to tumour size (P = 0.01) and fell significantly in patients following curative resection (P = 0.04), suggesting that circulating levels reflect tumour load. We tested the potential tumour marker characteristics of IGFBP-2 SDS against three endpoints: metastasis alone; local pelvic recurrence alone; and metastasis and recurrence combined. The sensitivities for IGFBP-2 alone (>/= + 2SD) were modest at 55%, 46%, and 52%, but in combination with CEA, increased substantially to 90%, 77% and 86%, respectively. We conclude that the serum IGF-II and IGFBP-2 profiles may provide insights into underlying biological mechanisms, and that serum IGFBP-2 may have an adjunct role in cancer surveillance in patients with colorectal cancer.en
dc.language.isoenen
dc.subjectColorectal Canceren
dc.subjectCancer Metastasisen
dc.subjectCancer Stagingen
dc.subjectBiological Tumour Markersen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 2-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshInsulin-Like Growth Factor II-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshNeoplasm Staging-
dc.subject.meshSensitivity and Specificity-
dc.subject.meshTumor Markers, Biological-
dc.titleElevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital NHS Trust, Manchester, M20 4BX.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.